Guides

Plain explanations of peptide reconstitution, syringe units, bacteriostatic water and storage — each one sourced, and explicit about where the sources run out.

22 guides, drawing on 80 distinct primary documents — FDA labels, regulator decisions, published trials and standards. None of them is a summary of other people’s articles, and where the primary record runs out the guide says so rather than filling the gap from secondary sources.

• Retatrutide Phase 3 Results and Approval Status

  TRIUMPH-1 through TRIUMPH-4 now have positive topline results, but retatrutide is still investigational. Here is what each phase 3 trial found, what remains unpublished, and why results are not approval.

• GLP-1 Injection Sites: What the Zepbound and Wegovy Labels Say

  Abdomen, thigh or upper arm, with similar absorption at all three. What each FDA label says about the arm, rotation, the 2-inch rule and insulin.

• Semax vs Selank: Structure, Study Doses and FDA Status

  Semax and Selank share a Pro-Gly-Pro tail and nothing else that matters: different parent peptides, different studied uses, and neither is FDA approved.

• Semax Nasal Spray: Dosage Claims vs Published Evidence

  Semax is not FDA approved and has no established U.S. dose. The human study amounts, nasal-spray formulation problem and FDA's 2026 evidence review, separated from vendor protocols.

• Selank Dosage and Withdrawal: What Studies Show

  The small human Selank studies used intranasal regimens, but there is no FDA-approved dose and no controlled evidence defining Selank withdrawal. Study data, limits and safety gaps in one place.

• What a Peptide Calculator Does, and How to Check One

  The same three lines of arithmetic sit under every peptide calculator. Here is what one can and cannot know about your vial, six checks that separate a working tool from a guessing one, and why the best-known “pepcalc” is a completely different kind of tool.

• How to Reconstitute a Peptide

  The arithmetic, the order of operations, and the three decisions that actually matter — with the parts that have a real source separated from the parts that do not.

• Bacteriostatic Water: What It Is and How Much to Use

  What is actually in the bottle, why benzyl alcohol is there, who must never receive it, and where the 28-day rule genuinely comes from.

• How to Read an Insulin Syringe

  Every mark on the barrel is a volume. Where 0.25 mL and 0.5 mL fall on a 1 mL syringe, why a 1 mL barrel often cannot draw an odd number of units, and what changes on U-40 and U-500.

• Insulin Syringe Units, U-100 and the 2.5× Error

  Why a unit is a volume and not a dose, why barrel size does not change the reading, and how a U-40 syringe produces a 2.5-fold overdose.

• How Long Does a Reconstituted Vial Last?

  The 28-day figure is about the diluent bottle, not your drug. What approved labels actually say, and why they disagree with each other.

• Is Semaglutide a Peptide?

  Yes — and the structural detail explains the once-weekly dosing, the Ozempic and Wegovy branding, and why compounded versions come as a powder when the approved ones do not.

• How Long Does Semaglutide Take to Work?

  Three different clocks get confused for one. The drug peaks in 1–3 days, reaches full level at 4–5 weeks, and reaches its maintenance dose at week 17 — and no trial has ever published a day-by-day onset of appetite suppression.

• How Long Does a GLP-1 Stay in Your System?

  Half-life, time to steady state and practical clearance for semaglutide, tirzepatide, dulaglutide, liraglutide and retatrutide — from the labels, plus why nothing you do speeds it up.

• Semaglutide with Methylcobalamin (B12): What the FDA Actually Says

  The FDA has a direct statement about combining semaglutide with vitamin B12, and it is not the one the marketing implies. No trial of the combination has ever been published.

• Is There a Semaglutide to Tirzepatide Conversion?

  No regulator or manufacturer publishes one, and the pharmacology explains why milligram equivalence is not definable. What the labels say to do instead.

• Semaglutide Side Effects: The Actual Percentages, by Dose

  The FDA label publishes the incidence of every common adverse reaction, at each dose, next to the placebo rate. Those tables are reproduced here in full — including the placebo column almost nobody shows you.

• Does Semaglutide Work?

  Yes, and the size of the effect is published to one decimal place — including the placebo arm. What is not published is a single efficacy figure for any compounded semaglutide product.

• Ozempic’s Generic Name — and Why There Is No Generic Ozempic

  Semaglutide is the generic name and Ozempic is a brand. That is a different question from whether a generic is on sale: none is approved in the United States, one is tentatively approved and blocked, and compounded semaglutide is not a generic at all.

• When Did Ozempic Come Out?

  Ozempic was approved by the FDA on 5 December 2017, for type 2 diabetes — not for weight loss. The full semaglutide approval timeline, every date read off the FDA's own application records.

• How Does Semaglutide Work?

  It activates the GLP-1 receptor — that part is settled. The rest of the label is more cautious than almost anything written about it: the weight effects are “likely” mediated by appetite, and for three approved indications the mechanism is stated as not established.

• What Is the Starting Dose of Compounded Tirzepatide?

  There isn't one. No compounded tirzepatide is FDA approved, so no approved dose exists for it — and the shortage that made compounding it lawful was declared resolved on 19 December 2024. What the approved labels start at, and why that is not the same answer.